Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis

Authors: Aditi Gupta, Wei Cao, Meenakshi A Chellaiah

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Background

Bone loss and pathological fractures are common skeletal complications associated with androgen deprivation therapy and bone metastases in prostate cancer patients. We have previously demonstrated that prostate cancer cells secrete receptor activator of NF-kB ligand (RANKL), a protein essential for osteoclast differentiation and activation. However, the mechanism(s) by which RANKL is produced remains to be determined. The objective of this study is to gain insight into the molecular mechanisms controlling RANKL expression in metastatic prostate cancer cells.

Results

We show here that phosphorylation of Smad 5 by integrin αvβ3 and RUNX2 by CD44 signaling, respectively, regulates RANKL expression in human-derived PC3 prostate cancer cells isolated from bone metastasis. We found that RUNX2 intranuclear targeting is mediated by phosphorylation of Smad 5. Indeed, Smad5 knock-down via RNA interference and inhibition of Smad 5 phosphorylation by an αv inhibitor reduced RUNX2 nuclear localization and RANKL expression. Similarly, knockdown of CD44 or RUNX2 attenuated the expression of RANKL. As a result, conditioned media from these cells failed to support osteoclast differentiation in vitro. Immunohistochemistry analysis of tissue microarray sections containing primary prostatic tumor (grade2-4) detected predominant localization of RUNX2 and phosphorylated Smad 5 in the nuclei. Immunoblotting analyses of nuclear lysates from prostate tumor tissue corroborate these observations.

Conclusions

Collectively, we show that CD44 signaling regulates phosphorylation of RUNX2. Localization of RUNX2 in the nucleus requires phosphorylation of Smad-5 by integrin αvβ3 signaling. Our results suggest possible integration of two different pathways in the expression of RANKL. These observations imply a novel mechanistic insight into the role of these proteins in bone loss associated with bone metastases in patients with prostate cancer.
Appendix
Available only for authorised users
Literature
1.
van der Gulden JW, Kiemeney LA, Verbeek AL, Straatman H: Mortality trend from prostate cancer in The Netherlands (1950–1989) 7. Prostate. 1994, 24: 33-38. 10.1002/pros.2990240108CrossRef
2.
Brawley OW: Prostate cancer epidemiology in the United States. World J Urol. 2012, 30: 195-200. 10.1007/s00345-012-0824-2CrossRef
3.
Carlin BI, Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma 1. Cancer. 2000, 88: 2989-2994. 10.1002/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-QCrossRef
4.
Sanchez-Sweatman OH, Orr FW, Singh G: Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis. 1998, 18: 297-305. 10.1159/000024522CrossRef
5.
Dougall WC: RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care. 2007, 1: 317-322. 10.1097/SPC.0b013e3282f335beCrossRef
6.
Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases12. JAMA. 2004, 292: 490-495. 10.1001/jama.292.4.490CrossRef
7.
Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-XCrossRef
8.
Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001, 107: 1235-1244. 10.1172/JCI11685PubMedCentralCrossRef
9.
Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 2003, 63: 7883-7890.
10.
Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC: RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008, 7: 2160-2169. 10.1158/1535-7163.MCT-08-0046CrossRef
11.
Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K: The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer2. Prostate. 2007, 67: 999-1009. 10.1002/pros.20592CrossRef
12.
Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ: Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 2005, 146: 1727-1736. 10.1210/en.2004-1211CrossRef
13.
Liao J, McCauley LK: Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev. 2006, 25: 559-571.CrossRef
14.
Baniwal SK, Khalid O, Sir D, Buchanan G, Coetzee GA, Frenkel B: Repression of Runx2 by androgen receptor (AR) in osteoblasts and prostate cancer cells: AR binds Runx2 and abrogates its recruitment to DNA. Mol Endocrinol. 2009, 23: 1203-1214. 10.1210/me.2008-0470PubMedCentralCrossRef
15.
Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB: Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004, 64: 4506-4513. 10.1158/0008-5472.CAN-03-3851CrossRef
16.
Brubaker KD, Vessella RL, Brown LG, Corey E: Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate. 2003, 56: 13-22. 10.1002/pros.10233CrossRef
17.
Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A. 2005, 102: 1454-1459. 10.1073/pnas.0409121102PubMedCentralCrossRef
18.
Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA: Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010, 29: 811-821. 10.1038/onc.2009.389PubMedCentralCrossRef
19.
Selvamurugan N, Shimizu E, Lee M, Liu T, Li H, Partridge NC: Identification and characterization of Runx2 phosphorylation sites involved in matrix metalloproteinase-13 promoter activation. FEBS Lett. 2009, 583: 1141-1146. 10.1016/j.febslet.2009.02.040CrossRef
20.
Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL: Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006, 25: 589-600.CrossRef
21.
Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD: Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 2008, 68: 7795-7802. 10.1158/0008-5472.CAN-08-1078PubMedCentralCrossRef
22.
Kitazawa R, Mori K, Yamaguchi A, Kondo T, Kitazawa S: Modulation of mouse RANKL gene expression by Runx2 and vitamin D3. J Cell Biochem. 2008, 105: 1289-1297. 10.1002/jcb.21929CrossRef
23.
Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo W-H: Interacton and functional cooperation of PEBP2/CBF with Smads. J Biol Chem. 1999, 274: 31577-31582. 10.1074/jbc.274.44.31577CrossRef
24.
Javed A, Afzal F, Bae JS, Gutierrez S, Zaidi K, Pratap J: Specific residues of RUNX2 are obligatory for formation of BMP2-induced RUNX2-SMAD complex to promote osteoblast differentiation. Cells Tissues Organs. 2009, 189: 133-137. 10.1159/000151719CrossRef
25.
Ito Y, Zhang YW: A RUNX2/PEBP2alphaA/CBFA1 mutation in cleidocranial dysplasia revealing the link between the gene and Smad. J Bone Miner Metab. 2001, 19: 188-194. 10.1007/s007740170041CrossRef
26.
Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T: Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol. 2000, 20: 8783-8792. 10.1128/MCB.20.23.8783-8792.2000PubMedCentralCrossRef
27.
Jun JH, Yoon WJ, Seo SB, Woo KM, Kim GS, Ryoo HM: BMP2-activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem. 2010, 285: 36410-36419. 10.1074/jbc.M110.142307PubMedCentralCrossRef
28.
Desai B, Rogers MJ, Chellaiah MA: Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer. 2007, 6: 18- 10.1186/1476-4598-6-18PubMedCentralCrossRef
29.
Cooper CR, Chay CH, Pienta KJ: The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia. 2002, 4: 191-194. 10.1038/sj.neo.7900224PubMedCentralCrossRef
30.
Weber GF, Ashkar S: Molecular mechanisms of tumor dissemination in primary and metastatic brain cancers. Brain Res Bull. 2000, 53: 421-424. 10.1016/S0361-9230(00)00379-8CrossRef
31.
Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F: Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J. 2002, 16: 1266-1268.
32.
Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J: Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004, 114: 1714-1725.PubMedCentralCrossRef
33.
Naor D, Sionov RV, Zahalka M, Rochman M, Holzmann B, Ish-Shalom D: Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Curr Top Microbiol Immunol. 1998, 231: 143-166. 10.1007/978-3-642-71987-5_9
34.
Sy MS, Guo YJ, Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med. 1991, 174: 859-866. 10.1084/jem.174.4.859CrossRef
35.
Gao AC, Lou W, Dong JT, Isaacs JT: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 1997, 57: 846-849.
36.
Noordzij MA, Van Steenbrugge GJ, Schroder FH, Van Der Kwast TH: Decreased expression of CD44 in metastatic prostate cancer. Int J Cancer. 1999, 84: 478-483. 10.1002/(SICI)1097-0215(19991022)84:5<478::AID-IJC5>3.0.CO;2-NCrossRef
37.
Tanne Y, Tanimoto K, Tanaka N, Ueki M, Lin YY, Ohkuma S: Expression and activity of Runx2 mediated by hyaluronan during chondrocyte differentiation. Arch Oral Biol. 2008, 53: 478-487. 10.1016/j.archoralbio.2007.12.007CrossRef
38.
Hayer S, Steiner G, Gortz B, Reiter E, Tohidast-Akrad M, Amling M: CD44 is a determinant of inflammatory bone loss. J Exp Med. 2005, 201: 903-914. 10.1084/jem.20040852PubMedCentralCrossRef
39.
Cao J, Singleton P, Majumdar S, Burghardt A, Bourguignon GJ, Halloran BP: Hyaluronan increases RANKL expression in mouse primary osteoblasts through CD44. A potential role in age-related bone loss. J Bone Miner Res. 2003, 18 (S2): S78-Ref Type: Abstract.
40.
Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S: Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem. 2007, 282: 10814-10825. 10.1074/jbc.M606991200CrossRef
41.
Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T: Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009, 26: 433-446. 10.1007/s10585-009-9242-2PubMedCentralCrossRef
42.
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL: CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008, 98: 756-765. 10.1038/sj.bjc.6604242PubMedCentralCrossRef
43.
Dhir R, Gau JT, Krill D, Bastacky S, Bahnson RR, Cooper DL: CD44 Expression in Benign and Neoplastic Human Prostates. Mol Diagn. 1997, 2: 197-204. 10.1016/S1084-8592(97)80029-XCrossRef
44.
Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS: The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 2005, 25: 8581-8591. 10.1128/MCB.25.19.8581-8591.2005PubMedCentralCrossRef
45.
Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR: The pathophysiology of HOX genes and their role in cancer. J Pathol. 2005, 205: 154-171. 10.1002/path.1710CrossRef
46.
Roccisana JL, Kawanabe N, Kajiya H, Koide M, Roodman GD, Reddy SV: Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells. J Biol Chem. 2004, 279: 10500-10507.CrossRef
47.
Cao JJ, Singleton PA, Majumdar S, Boudignon B, Burghardt A, Kurimoto P: Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44. J Bone Miner Res. 2005, 20: 30-40. 10.1359/JBMR.041014CrossRef
48.
Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ: PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011, 71: 1668-1679. 10.1002/pros.21383PubMedCentralCrossRef
49.
Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X: ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo. 2011, 25: 69-76.
50.
Mori K, Kitazawa R, Kondo T, Maeda S, Yamaguchi A, Kitazawa S: Modulation of mouse RANKL gene expression by Runx2 and PKA pathway. J Cell Biochem. 2006, 98: 1629-1644. 10.1002/jcb.20891CrossRef
51.
Chang SF, Chang CA, Lee DY, Lee PL, Yeh YM, Yeh CR: Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad. Proc Natl Acad Sci U S A. 2008, 105: 3927-3932. 10.1073/pnas.0712353105PubMedCentralCrossRef
52.
Robertson BW, Bonsal L, Chellaiah MA: Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer. 2010, 9: 260- 10.1186/1476-4598-9-260PubMedCentralCrossRef
53.
Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R: Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem. 2002, 277: 2468-2476. 10.1074/jbc.M105947200CrossRef
54.
Robertson BW, Chellaiah MA: Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res. 2010, 316: 1-11. 10.1016/j.yexcr.2009.10.012PubMedCentralCrossRef
55.
van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR: The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem. 2010, 109: 828-837.PubMedCentral
56.
Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J: RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem. 2006, 97: 1-17. 10.1002/jcb.20664CrossRef
57.
Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X: Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res. 2009, 15: 4322-4335. 10.1158/1078-0432.CCR-08-3157CrossRef
58.
Afzal F, Pratap J, Ito K, Ito Y, Stein JL, van Wijnen AJ: Smad function and intranuclear targeting share a Runx2 motif required for osteogenic lineage induction and BMP2 responsive transcription. J Cell Physiol. 2005, 204: 63-72. 10.1002/jcp.20258CrossRef
59.
Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS, Lian JB: Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci U S A. 2002, 99: 8048-8053. 10.1073/pnas.112664499PubMedCentralCrossRef
60.
Lee KS, Hong SH, Bae SC: Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene. 2002, 21: 7156-7163. 10.1038/sj.onc.1205937CrossRef
61.
Selvamurugan N, Kwok S, Partridge NC: Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem. 2004, 279: 27764-27773. 10.1074/jbc.M312870200CrossRef
62.
Leboy P, Grasso-Knight G, D’Angelo M, Volk SW, Lian JV, Drissi H: Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am. 2001, 83-A (Suppl 1): S15-S22.
63.
Hjelmeland AB, Schilling SH, Guo X, Quarles D, Wang XF: Loss of Smad3-mediated negative regulation of Runx2 activity leads to an alteration in cell fate determination. Mol Cell Biol. 2005, 25: 9460-9468. 10.1128/MCB.25.21.9460-9468.2005PubMedCentralCrossRef
64.
Ohyama Y, Tanaka T, Shimizu T, Matsui H, Sato H, Koitabashi N: Runx2/Smad3 complex negatively regulates TGF-beta-induced connective tissue growth factor gene expression in vascular smooth muscle cells. J Atheroscler Thromb. 2012, 19: 23-35. 10.5551/jat.9753CrossRef
65.
Tanikawa R, Tanikawa T, Hirashima M, Yamauchi A, Tanaka Y: Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochem Biophys Res Commun. 2010, 394: 317-322. 10.1016/j.bbrc.2010.02.175CrossRef
66.
Wang CY, Lee LH: Mutagenicity and antibacterial activity of hydroxamic acids. Antimicrob Agents Chemother. 1977, 11: 753- 10.1128/AAC.11.4.753PubMedCentralCrossRef
67.
Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D: Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate. 1999, 40: 150-158. 10.1002/(SICI)1097-0045(19990801)40:3<150::AID-PROS2>3.0.CO;2-7CrossRef
68.
Chellaiah M, Kizer N, Silva M, Alvarez U, Kwiatkowski D, Hruska KA: Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol. 2000, 148: 665-678. 10.1083/jcb.148.4.665PubMedCentralCrossRef
69.
Gupta A, Lee BS, Khadeer MA, Tang Z, Chellaiah M, Abu-Amer Y: Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J Bone Miner Res. 2003, 18: 669-685. 10.1359/jbmr.2003.18.4.669CrossRef
70.
Desai B, Ma T, Zhu J, Chellaiah MA: Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem. 2009, 108: 272-284. 10.1002/jcb.22248CrossRef
71.
Chellaiah M, Hruska KA: Osteopontin stimulates gelsolin associated phosphoinositide levels and PtdIns 3-hydroxyl kinase. Mol Biol Cell. 1996, 7: 743-753.PubMedCentralCrossRef
72.
Ma T, Sadashivaiah K, Chellaiah MA: Regulation of sealing ring formation by L-plastin and cortactin in osteoclasts. J Biol Chem. 2010, 285: 29911-29924. 10.1074/jbc.M109.099697PubMedCentralCrossRef
73.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262CrossRef
74.
Schneider A, Younis RH, Gutkind JS: Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. Neoplasia. 2008, 10: 1295-1302.PubMedCentralCrossRef
75.
Singh IS, Gupta A, Nagarsekar A, Cooper Z, Manka C, Hester L: Heat shock co-activates interleukin-8 transcription. Am J Respir Cell Mol Biol. 2008, 39: 235-242. 10.1165/rcmb.2007-0294OCPubMedCentralCrossRef
76.
Feng P, Li TL, Guan ZX, Franklin RB, Costello LC: Direct effect of zinc on mitochondrial apoptogenesis in prostate cells. Prostate. 2002, 52: 311-318. 10.1002/pros.10128PubMedCentralCrossRef
Metadata
Title
Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis
Authors
Aditi Gupta
Wei Cao
Meenakshi A Chellaiah
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-66

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue

Research

Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection

Research

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

Research

MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma

Retraction Note

Retraction Note: Application of cytology and molecular biology in diagnosing premalignant or malignant oral lesions

Research

Loss of HLTF function promotes intestinal carcinogenesis

Research

Dichotomy effects of Akt signaling in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits